AbstrAct background Prevention of sexually transmitted infection (STI) incidence in England is a high priority, particularly among young people, men who have sex with men (MSM) and black ethnic minorities. An economic evaluation of condom distribution programmes (CDPs) to reduce STI transmission is presented. Methods An economic model using a Bernoulli process estimated the number of people acquiring an STI as a function of its prevalence, transmission rate, condom use, condom failure rate and number of sexual contacts. Models were developed for young people (13-24 years), black ethnic minorities, MSM and the general English population. Effectiveness evidence came from a recent systematic review. For young people, a CDP was modelled (relative risk for condom use=1.23), along with an exploratory analysis of the impact on unintended pregnancies. For other populations, threshold analyses were used to identify the combination of costs and effect size required to make a programme cost-effective. results The base case predicted that CDP for all young people in England could avert 5123 STI cases per annum, with an incremental cost-effectiveness ratio of £17 411. In addition, it could avert 118 pregnancies and 82 abortions and save £333 000 in associated costs. Schemes for black ethnic minorities and MSM could also be cost-effective even with relatively high costs and small effect sizes. conclusion CDPs for young people are likely to be cost-effective or cost-saving. CDPs for other high-risk populations may also be cost-effective if they can increase condom use, since high HIV prevalence in these groups imposes a considerable health and cost burden.
IntroductIon
Sexually transmitted infections (STIs) have detrimental impacts on quality of life and survival and impose a burden on the UK National Health Service (NHS). In 2015, there were 435 000 new diagnoses in England with a 20% and 11% increase observed in the incidence of syphilis and gonorrhoea respectively compared with 2014. 1 STI incidence is highest among people under the age of 25, men who have sex with men (MSM) and black ethnic minorities. 1 Condoms can protect against transmission of many STIs including gonorrhoea, chlamydia, syphilis and HIV. 2 The 2014-2015 increase in syphilis and gonorrhoea diagnoses is attributed to high levels of unprotected sex. 1 Reasons condoms are not used or are used incorrectly include cost, lack of knowledge and social norms. Condom distribution programmes (CDPs) aim to overcome these challenges by providing condoms free of charge or at reduced prices, possibly accompanied by training or support, such as the C-card programme (the multicomponent programme most commonly offered to young people in England). 3 The Department of Health referred the topic 'Sexually transmitted infections: condom distribution schemes' to the National Institute for Health and Care Excellence (NICE) to develop public health guidance. 4 NICE considers evidence for effectiveness and cost-effectiveness in developing recommendations. A systematic literature review highlighted a paucity of evidence for the costeffectiveness of CDPs in the UK. 5 Therefore, we developed an economic model to evaluate the cost-effectiveness of CDPs. This study presents our economic evaluation of CDPs for the general population and for targeted at-risk groups: young people, MSM and black ethnic minorities.
Methods Population
We based the population on English 2011 census data by gender and 5-year age group. 6 Cohorts of the appropriate age-range and gender were selected to model each of the target groups.
Model
We developed an economic model which estimated 'steady state' STI acquisition and associated cost-effectiveness. The model uses an established Bernoulli process which estimates the number of STIs in a cohort of people 7 and has been used in other economic evaluations, including NICE Public Health guidelines. 8 9 The model predicts the proportion of people acquiring an STI in a given gender-specific and age-specific group (W) as a function of the STI prevalence (v), the proportion of sexually active people using condoms (g), the STI transmission rate (t), the condom failure rate (k) and the annual number of sexual contacts in that subgroup (s):
The impact of a CDP was captured by changing the proportion of people using condoms (g) according to the effectiveness of the intervention
Research report
A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England 12 reported a controlled trial. The studies were located in USA 10 11 and Sweden. 12 No studies evaluated interventions in the UK. The review concluded that there was some limited evidence to show that multicomponent programmes in high schools can increase condom use. The highest quality study 12 was chosen to give the estimated effectiveness in the base case (also the study with the largest effect size). It is worth noting that the population (students aged 17) and intervention (schoolbased) used in this trial was not a perfect match for the C-card programme, which targets a broader age-range (typically ages [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and in a wider range of settings (including sexual health, genito-urinary medicine clinics, youth services and schools). The base case uses an age range of 13-24 to replicate C-card. However, since the evidence is taken from a younger population, a scenario for ages 13-18 years is also presented.
The review identified one study targeting black ethnic minorities. 13 This study was located in USA and targeted those with high levels of syphilis. It reported that condom use increased, although study quality was poor and data were not presented.
The review identified one single component programme targeting MSM. However, this study did not ask about condom use at last anal intercourse and despite improvements in condom possession rate, a small increase in men saying they 'had anal intercourse without a condom simply because there was no condom available' was reported. 14 The review identified only one study looking at reduced-price condom provision. 15 Although this study showed increased condom purchasing, no data were collected on condom use.
Due to the lack of effectiveness evidence for programmes for black ethnic minorities, MSM and the general population via discounted provision, a threshold analysis was carried out for these groups assessing a range of effectiveness and cost levels, to identify the combination of costs and effectiveness required to make a programme cost-effective at a threshold of £20 000 per QALY gained, or dominant (QALY-improving and cost-saving). £20 000 per QALY is the notional threshold used by NICE to assess whether interventions are considered cost-effective if funded by the NHS.
Quality-adjusted life years
QALY loss was modelled either using an absolute QALY reduction per STI obtained from the literature or a disutility per STI multiplied by time affected. For HIV the QALY decrement reported by Farnham et al 16 was used, assuming people were diagnosed when their CD4 count was above 500, and including QALYs lost due to infections and reduced life-expectancy, with a 3% annual discounted rate, this being a US study. All QALY decrements are shown in table 1. 9 16-37 
sexually transmitted infections
The STIs modelled are chlamydia, gonorrhoea, syphilis, HIV and pelvic inflammatory disease (PID), which can follow chlamydia or gonorrhoea in women. Prevalence of chlamydia, gonorrhoea and syphilis by risk group, age and gender were taken from Public Health England (PHE) cases in 2014. 38 HIV prevalence was based on new cases from PHE. 39 Prevalence estimates are shown in table 2. Table 1 contains all the parameters of the STI model. 9 16-37 Age-specific and gender-specific proportions of people who are sexually active and rates of sexual contact were taken from Mercer et al, 28 with under-13s assumed not to be sexually active. The percentage of men who are MSM (2.8%) was taken from the National Survey of Sexual Attitudes and Lifestyles. 40 Age-specific rates of routine condom use for young people, black ethnic minorities and the general population were reported by the Office of National Statistics, 20 with under-16s assumed the same as young people ages 16-19 years. MSM condom use was taken from the 2008 UK Gay Men's Sex Survey 29 and applied across all ages. Condom failure rate was based on Macaluso et al. 27 Evidence on the probability of transmission per unprotected sexual contact is old and limited by the ethical implications of this research. Rates and sources are presented in table 1. 9 16-37 Rates of PID as a function of the number of cases of chlamydia and gonorrhoea were based on two studies. 30 
other parameters

costs
We used an NHS and personal social services perspective, a cost year of 2015 and a 3.5% annual discount rate. All costs are shown in table 1. 9 16-37 We include in STI treatment costs the appropriate number of consultations, tests and treatments using the British National Formulary 41 and unit costs of health and social care. 17 Costs of PID were taken from a previously published report. 11 The UK lifetime HIV treatment cost was taken from Nakagawa et al, 19 using the more conservative of their two estimates (based on the assumption of switching to generic drugs once pharmaceutical patents expire and assuming generic drugs cost 20% of the branded versions). It was thought important to use the more conservative estimate here to avoid potentially overestimating the costs.
A rapid search identified intervention costs for five local C-card programmes in England and Wales. 20-23 42 Using published population statistics for ages 13-24 for each area, 6 we calculated that four of the five programmes gave costs between £0.33 and £0.68 per head of teenage population per annum (the other had higher costs of £1.21 per head). An estimated cost of £0.48 (95% CI £0.19 to £0.76) per head of teenage population was chosen as the average of the four lowest-cost published programmes. This cost was validated using a bottom-up costing exercise informed by experts with experience of running programmes.
uncertainty
A probabilistic sensitivity analysis of 5000 runs was conducted to assess the impact of parameter uncertainty on the model output. All results presented are probabilistic. 
Continued research report
The systematic review identified three studies of multicomponent programmes in young people. In our base case, we used the highest-quality study, but this also had the largest effect size (RR=1.23). As a sensitivity analysis, we calculated the incremental cost-effectiveness ratio (ICER) associated with a condom use relative risk of 1.11 (the lower effect size from the three studies). 
research report
There is reasonable evidence in the literature that condom failure rates reduce with experience. 43 A scenario was modelled for young people which assumed reduced condom breakage (OR of 0.8) based on Macaluso et al. 27 Base-case HIV prevalence estimates are from diagnosis rates and may underestimate the true prevalence of HIV. Therefore, higher HIV prevalence scenarios were modelled using estimated HIV prevalence by risk group from the 2015 HIV Situation Report 44 and in addition using updated figures for MSM in London. 39 In the general population, a scenario used rates from the NICE HIV testing guideline. 8 To validate our model, we compared our results for young people, with and without a CDP, to the 2014-2015 PHE data for STI prevalence. 45 The focus of NICE's guideline was STIs. However, an exploratory analysis was undertaken, to understand the impact of the interventions in young people aged of 14-18 years on pregnancy, using an existing model of contraceptive interventions 46 and assuming that all pregnancies within this age group were unintended. It was assumed that 50% of the unintended teenage pregnancies would be prevented and 50% delayed until age 19-24. The probability of becoming pregnant and of having an abortion by age were updated using the latest national statistics. 47 The model was updated to use the same condom failure rate as the STI model. Costs were expressed in 2014/15 prices. 48 
resuLts
Results for young people aged 13-24 are summarised in table 3. The analysis predicts that an intervention with effectiveness taken from Larsson et al 12 and with costs in the region of a typical C-card programme would be expected to avert 5123 cases of STIs (95% CI 439 to -12 441), of which over 4200 (383 to 10 420) are chlamydia. The programme is estimated to lead to a gain of 55 14 QALYs and a positive net cost (programme cost minus healthcare savings) of £957 622 (-£2 723 496 to £2 947 501), giving an incremental cost per QALY gained of £17 411 compared with no CDP.
The evidence for effectiveness was for a younger age group, however. With age 13-18 years only, the programme was not cost-effective at NICE's £20 000 level (ICER = £45,856).
The result was sensitive to reducing the effectiveness estimate. With a reduced change in condom use (R=1.11), the ICER in the 13-24 age group increased to £88 979. The results of the scenario analysis where condom breakage was reduced led to an ICER of £14 469. In the scenario with higher HIV prevalence the increase in HIV cases averted makes the programme costsaving overall (£10m healthcare savings compared with £3.5m programme costs across England in the target population).
In an additional exploratory analysis of pregnancy outcomes, an England-wide programme with base-case costs and effectiveness is predicted to avoid approximately 118 pregnancies, 82 abortions and save £333 000 across England in associated costs (not included in our presented results). This would increase to £12m if government funded benefits were included. Figure 1 illustrates the results of threshold analyses for the base case in each population. The result shows that CDPs are much more likely to be cost-effective in populations with high prevalence of HIV (MSM and black ethnic minorities) and that even programmes with relatively small effect sizes and high costs can be cost-saving in these groups. Meanwhile, programmes for young people can be cost-effective or cost-saving as long as costs can be controlled to around 40-60p per person, depending on effectiveness. Untargeted programmes for the general population are only likely to be cost-effective at very low cost.
Results of model validation are shown in figure 2 . The model correctly shows a decrease in chlamydia diagnoses, although it overestimates this decrease by approximately 40%. Similarly, the model overestimates the decrease in gonorrhoea diagnoses, which actually increased among men aged 20-24 years. Syphilis remains fairly constant in both the model and PHE data, except the model shows a small decrease in cases for men aged 20-24 years and PHE data show an increase.
dIscussIon
The cost-effectiveness of CDPs is heavily influenced by the underlying STI prevalence and sexual activity levels of the population.
We found that the ICER for CDP targeted at young people, such as the C-card programme was likely to be cost-effective at NICE's £20 000/QALY threshold. Threshold analyses suggest that CDPs for MSM and black ethnic minorities can also be cost-effective even if the programme cost per person is fairly high, whereas for the general population in which prevalence and risk of transmission are lower, costs have to be very low in order for programmes to be cost-effective.
HIV prevalence is particularly important in determining cost-effectiveness. This is because although HIV is relatively less prevalent than other STIs, the cost and QALY loss per case are much higher. Our study confirms findings 49 50 that CDPs for populations with high HIV prevalence can be cost-effective when condom usage is increased by as little as 2% (RR=1.02).
Although the focus of NICE's guidance was STI prevention, our analysis suggests that including the potential impact on reduced conception rates makes it very likely that a CDP would be cost-saving. This analysis was somewhat speculative, especially in terms of government-funded benefit costs, since the benefits landscape has changed considerably since the original model was developed in 2010. This is the first study to estimate the cost-effectiveness of CDPs in the UK. It combines data from several different sources and gives an indication of the potential economic impact of C-card programmes which has not previously been reported. However, research report the analysis is limited by the quality and availability of evidence. It assumes that all sexually active people within one age band behave in the same way, with an average number of sexual contacts and the same probability of condom use without a CDP. In reality, there will be some people who are more sexually active than others, some people in monogamous relationships and some with higher numbers of sexual partners and condom usage rates will differ according to these (and other) factors. Validating the binomial model of disease prevalence is challenging because the current distribution and uptake of CDPs in England are unknown and because CDPs are often linked to other services such as STI testing which impact diagnosis rates and confound prevalence estimates. We expected the model results without CDP to show more STIs than the PHE 2015 data and the model results with CDP to show fewer STIs than the PHE 2015, since in reality a number of CDPs programmes are already in operation. We saw that for all STIs, the model results with and without STIs were lower than the PHE data. The binomial model of steady state disease prevalence appears therefore to underestimate STI transmission and therefore potentially underestimates the effect of increased condom usage on STI reduction, which suggests that the estimates of CDP cost-effectiveness are likely to be conservative.
We used a static model for estimating the transmission of STIs, assuming a constant underlying prevalence of each STI. In reality, for STIs with long recovery periods or no recovery, the underlying prevalence will increase. This may partly explain why our model underpredicts STI prevalence. This effect may be particularly important in the case of HIV, for which both costs and quality of life effects are high. In addition, our model does not take account of the potential transmission of infections such as HIV and syphilis from mother to baby, where condom use before and during pregnancy may have the additional impact of reducing infection or other severe health impacts on fetuses or new-borns.
Our model was not able to account for any effects of increased condom use on undiagnosed STIs. There may also be variability around CDP costs. We used the average from four C-card programmes with similar costs as these closely corresponded to a bottom-up costing exercise and excluded one programme that had higher costs.
Our model considers STI transmission over a 1-year period, which may underestimate the benefit of CDPs for two reasons. First, since new STI diagnoses are a function of initial prevalence, the rates of new diagnoses for CDP and a comparator without CDP, diagnoses would be expected to diverge over time 
What this study adds
► An economic model to evaluate the cost-effectiveness of condom distribution programmes (CDPs) was developed. It suggested that an intervention which provides free condoms along with some education and support to young people in England could be expected to avert 5123 new sexually transmitted infections per annum. This would lead to improved health-related quality of life and treatment cost savings, resulting in an estimated incremental cost of £17 411 per quality-adjusted life-year gained compared with no programme.
► CDPs for men who have sex with men and black ethnic minorities may also be cost-effective even with small increases in condom use since these groups have higher prevalence of HIV, which has a big impact on life-expectancy, quality of life and treatment costs.
research report and the incremental effectiveness would increase. Second, there may be longer-term benefits of engaging people with CDPs and sexual health services, potentially resulting in fewer STIs at little or no extra cost. More research of better quality is needed on the effectiveness of CDPs. Research that investigates change in condom usage would also allow the economic models to be updated, while research investigating the relationship between CDP implementation and STI incidence would remove the need for an epidemiological model. Evaluations of C-card programmes are particularly important to understand both their effectiveness and cost-effectiveness. Furthermore, comparative evaluation of different modes of implementation of C-card programmes and different population subgroups or age groups would allow policy makers to understand how these programmes may be optimally delivered and targeted.
We conclude that CDPs for young people are likely to be good value for money at currently accepted cost-effectiveness thresholds and that CDPs for other high-risk populations may also be economically attractive. Given the substantial public health burden associated with STIs, it is important that efforts are made to reduce their transmission and this suggests that CDPs are likely to be a cost-effective approach. programmes. METRO also provided data to support this, which was extremely useful in validating the costs used in the model. What is already known on this subject ► A total of 435 000 sexually transmitted infections (STIs) were diagnosed in England in 2015, with substantial yearon-year increases in syphilis and gonorrhoea. Incidence was particularly high in young people under the age of 25, men who have sex with men and black ethnic minorities. ► Condom distribution programmes (CDPs) provide condoms free or at reduced prices, sometimes with training or support, to try and increase condom use and prevent the spread of STIs.
► A recent systematic literature review highlighted a paucity of relevant evidence evaluating the cost-effectiveness of CDPs in the UK. 
